Prof Ghassan Abou-Alfa presents data from the ClarIDHy trial during a press conference at the 2019 ESMO congress.
This was a phase III trial evaluating the use of the targeted therapy ivosidenib for advanced cholagiocarcinoma patients with the isocitrate dehydrogenase 1 (IDH1) mutation.
Watch Prof Abou-Alfa's interview with ecancer here.
Watch Dr Angela Lamarca's comment here.
Read more about the study here.